Treatment Action Group

"The policy moves made by the Trump administration, this year alone, have been illogical," Suraj Madoori writes.

Research indicates that robust universal health coverage could contribute to reducing HIV incidence by improving access to proven tools for reducing transmission.

Reining in prescription drug prices isn't so much a potential benefit of universal health care, but rather a factor in its affordability and success.

"Exportation of the insurance model to developing countries, especially at a time of global austerity, institutionalizes the retreat from the social contract at just the moment when investment in infectious diseases could result in the elimination of...

"Recent studies of Black communities' attitudes regarding HIV show that ... rumors and conspiracies have continued to persist, and yet few, if any, public health approaches have been funded to directly engage communities in these myths and to provide...

People with hepatitis C virus and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV medicines.

"The story of U.S. drug pricing run amok isn't just about corporate arrogance and avarice -- it is also about government permissiveness and inaction," write Tim Horn, Erica Lessem and Kenyon Farrow.

We've heard a lot about the plan to end AIDS in New York, and here the plan is discussed in detail.

According to Treatment Action Group, "access to essential medicines is a part of the human right to health." Here, they explain how much red tape is in the way of that right.

HCV diagnostic assays (tests) are important for four specific reasons: 1) to protect the blood supply; 2) to diagnose if an individual is acutely infected with HCV; 3) to determine if an individual is a chronic carrier; and 4) to evaluate the effect ...